FDA approves marketing of postnatal test for developmental disabilities

Author(s):

On Jan. 17, the U.S. Food and Drug Administration (FDA) announce that it has authorized for marketing the Affymetrix CytoScan Dx Assay, which can detect chromosomal variations that may be responsible for a child’s developmental delay or intellectual disability. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here